Key Insights
The Philippines Oral Anti-Diabetic Drug Market is poised for significant expansion, projected to reach $202.20 million by 2025. This robust growth is fueled by an anticipated Compound Annual Growth Rate (CAGR) exceeding 4.00% from 2025 to 2033. The rising prevalence of diabetes, particularly Type 2 diabetes, coupled with an increasing awareness of effective treatment options, are the primary drivers. Furthermore, an aging population and a growing emphasis on lifestyle management are contributing to the sustained demand for oral anti-diabetic medications. Key drug classes such as DPP-4 inhibitors and SGLT2 inhibitors are expected to witness substantial uptake due to their favorable efficacy and safety profiles. The market is also influenced by government initiatives aimed at improving healthcare access and managing chronic diseases, further bolstering its positive trajectory.
Philippines Oral Anti-Diabetic Drug Market Market Size (In Million)
The landscape of the Philippines Oral Anti-Diabetic Drug Market is characterized by a competitive environment with major global pharmaceutical players actively engaged. While the market shows strong growth potential, certain factors could present challenges. These may include the cost of newer, more advanced oral anti-diabetic drugs, potential accessibility issues in remote areas, and the impact of generic competition. However, the increasing focus on preventive healthcare and the development of innovative treatment strategies are expected to outweigh these restraints. The market segmentation by indication clearly highlights the dominance of Type 2 Diabetes, reflecting global trends. The market is also witnessing advancements in drug development, with a continuous pipeline of novel oral anti-diabetic agents expected to enter the market, offering enhanced therapeutic benefits and further driving market expansion.
Philippines Oral Anti-Diabetic Drug Market Company Market Share
Philippines Oral Anti-Diabetic Drug Market: Comprehensive Analysis & Forecast (2019-2033)
This in-depth report provides a comprehensive analysis of the Philippines oral anti-diabetic drug market, a critical segment within the nation's growing healthcare landscape. Delving into market dynamics, growth trends, and competitive intelligence, this study offers actionable insights for pharmaceutical manufacturers, distributors, and healthcare stakeholders. With a focus on oral anti-diabetic medications, the report covers Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes indications, segmented by Drug Class including Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D2 Receptor Agonist, SGLT2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, and Meglitinides. The Philippines oral anti-diabetic drug market size is projected to witness substantial growth, driven by increasing diabetes prevalence and evolving treatment paradigms. This report leverages extensive market data for the base year 2025 and forecasts to 2033, building upon historical data from 2019–2024. Explore the parent market and child market segments to understand the intricate relationships and growth drivers within this vital sector.
Philippines Oral Anti-Diabetic Drug Market Market Dynamics & Structure
The Philippines oral anti-diabetic drug market is characterized by a moderately concentrated structure, with a few key global players holding significant market shares. Technological innovation is a primary driver, particularly in the development of novel drug classes like SGLT2 inhibitors and DPP-4 inhibitors, offering improved efficacy and safety profiles. The regulatory framework, overseen by the Philippine Food and Drug Administration (FDA), plays a crucial role in market access and product approvals. Competitive product substitutes are evolving, with a growing emphasis on combination therapies and newer oral agents that offer enhanced glycemic control and reduced cardiovascular risks. End-user demographics are shifting, with an aging population and a rising incidence of lifestyle-related chronic diseases, including Type 2 Diabetes, significantly influencing market demand. Mergers and acquisitions (M&A) are a notable trend, as companies seek to expand their portfolios, gain market access, and achieve economies of scale.
- Market Concentration: Dominated by multinational pharmaceutical giants, with a growing presence of local manufacturers exploring generic opportunities.
- Technological Innovation: Focus on developing drugs with improved efficacy, reduced side effects, and favorable cardiovascular outcomes.
- Regulatory Framework: Strict adherence to FDA guidelines for drug registration, manufacturing, and post-market surveillance.
- Competitive Product Substitutes: Increasing competition from newer oral anti-diabetic agents and the growing market for diabetes management devices.
- End-User Demographics: Rising prevalence of Type 2 Diabetes, driven by lifestyle changes and an aging population, fuels demand.
- M&A Trends: Strategic acquisitions and partnerships aimed at portfolio expansion and market penetration.
Philippines Oral Anti-Diabetic Drug Market Growth Trends & Insights
The Philippines oral anti-diabetic drug market is poised for significant expansion, driven by a confluence of factors including a burgeoning diabetic population, increasing healthcare expenditure, and a growing awareness of diabetes management. The market size evolution is directly linked to the escalating prevalence of Type 2 Diabetes, which is a major concern in the Philippines due to changing dietary habits and sedentary lifestyles. Adoption rates of newer oral anti-diabetic drugs, such as DPP-4 inhibitors and SGLT2 inhibitors, are on an upward trajectory as healthcare professionals and patients recognize their superior efficacy and better safety profiles compared to older drug classes like Sulfonylureas. Technological disruptions, including advancements in drug formulation and combination therapies, are further enhancing treatment outcomes and patient compliance. Consumer behavior shifts are also playing a pivotal role, with a growing preference for oral medications over injectable therapies for convenience and adherence, especially for long-term management of chronic conditions like diabetes. The market penetration of these advanced oral anti-diabetic drugs is expected to increase substantially over the forecast period. The CAGR for the Philippines oral anti-diabetic drug market is projected to be robust, reflecting these positive trends. The increasing affordability of certain oral anti-diabetic drugs through generic manufacturing also contributes to wider accessibility, thereby expanding the market reach. Furthermore, government initiatives aimed at improving diabetes care access and awareness programs are indirectly supporting market growth by educating the public and encouraging timely diagnosis and treatment. The Philippines oral anti-diabetic drug market growth is also influenced by the overall economic development of the country and the increasing disposable income, which allows for greater investment in healthcare.
Dominant Regions, Countries, or Segments in Philippines Oral Anti-Diabetic Drug Market
Within the Philippines oral anti-diabetic drug market, Type 2 Diabetes stands out as the most dominant indication driving market growth. This dominance is primarily attributed to the Philippines' alarming statistics regarding the prevalence of Type 2 Diabetes, which is intricately linked to lifestyle factors such as unhealthy diets, obesity, and a lack of physical activity. Consequently, Biguanides, particularly Metformin, continue to hold a substantial market share as the first-line therapy for Type 2 Diabetes, owing to their efficacy, safety, and affordability. However, the market is witnessing a significant surge in the adoption of newer drug classes like DPP-4 Inhibitors and SGLT2 Inhibitors. These advanced medications are gaining traction due to their superior glycemic control, reduced risk of hypoglycemia, and significant cardiovascular and renal benefits, making them increasingly preferred for patients with Type 2 Diabetes, especially those with comorbidities. Economic policies that encourage the uptake of evidence-based treatments and the presence of a strong network of healthcare providers across urban and semi-urban areas are crucial factors supporting the dominance of these segments. Infrastructure development in the healthcare sector, including the establishment of specialized diabetes clinics and improved access to diagnostic facilities, further facilitates the diagnosis and management of Type 2 Diabetes, thereby boosting the demand for oral anti-diabetic drugs. Market share analysis reveals that while Biguanides command a large volume, the higher price points and superior value proposition of DPP-4 Inhibitors and SGLT2 Inhibitors contribute significantly to market value. The growth potential for these advanced oral anti-diabetic drug classes remains exceptionally high as awareness and physician prescribing patterns evolve. Gestational Diabetes is a growing segment, influenced by increasing maternal age and a rise in obesity rates among pregnant women. While Type 1 Diabetes is a chronic condition requiring lifelong management, its prevalence is lower compared to Type 2 Diabetes, thus representing a smaller segment within the oral anti-diabetic drug market. The market share of other drug classes like Alpha-Glucosidase Inhibitors and Sulfonylureas is steadily being challenged by the newer agents, although they still find application in specific patient populations or as part of combination therapy due to their established efficacy and cost-effectiveness in certain scenarios.
Philippines Oral Anti-Diabetic Drug Market Product Landscape
The Philippines oral anti-diabetic drug market is characterized by a dynamic product landscape driven by continuous innovation and the introduction of advanced therapeutic agents. Key product innovations focus on enhancing efficacy, improving patient convenience, and mitigating adverse effects. This includes the development of novel drug formulations, such as extended-release versions and combination pills that consolidate multiple active ingredients into a single dosage, thereby improving patient adherence. DPP-4 Inhibitors and SGLT2 Inhibitors represent significant advancements, offering robust glycemic control and distinct benefits such as weight loss and cardiovascular protection, which are highly sought after by both patients and healthcare professionals. The introduction of new chemical entities within these classes, along with the expansion of their indications to include specific patient subgroups or comorbid conditions, continues to shape the market. Generic versions of established oral anti-diabetic drugs also play a crucial role, ensuring affordability and broader market access. Unique selling propositions often revolve around improved safety profiles, reduced risk of hypoglycemia, and positive impacts on cardiovascular and renal health, aligning with the evolving needs of diabetes management.
Key Drivers, Barriers & Challenges in Philippines Oral Anti-Diabetic Drug Market
The Philippines oral anti-diabetic drug market is propelled by several key drivers. The escalating prevalence of diabetes, largely driven by lifestyle factors and an aging population, creates a substantial and growing patient pool. Increasing healthcare expenditure and a growing awareness of chronic disease management among the populace further fuel market growth. Technological advancements in drug development, leading to more efficacious and safer oral anti-diabetic medications, are also significant drivers. Government initiatives aimed at improving public health and access to medicines contribute positively.
However, the market faces certain barriers and challenges. The high cost of newer, branded oral anti-diabetic drugs can be a significant restraint for a considerable portion of the population, impacting market penetration. Regulatory hurdles and lengthy approval processes for new drugs can also slow down market entry. Intense competition from generic manufacturers, while beneficial for affordability, can put pressure on profit margins for branded products. Supply chain disruptions, especially for imported raw materials or finished goods, can affect product availability. Furthermore, the continued reliance on older, less effective drug classes in certain patient segments due to cost considerations presents a challenge to the widespread adoption of advanced therapies.
Emerging Opportunities in Philippines Oral Anti-Diabetic Drug Market
Emerging opportunities in the Philippines oral anti-diabetic drug market lie in several key areas. The untapped potential within the Gestational Diabetes segment presents a significant avenue for growth, given the rising incidence. The increasing demand for combination therapies that simplify treatment regimens and improve patient adherence offers fertile ground for innovation and market expansion. Furthermore, the growing awareness of the cardiovascular and renal benefits associated with newer drug classes like SGLT2 inhibitors and GLP-1 receptor agonists (though primarily injectable, their oral formulations are emerging and will impact oral market perception) creates an opportunity for market penetration, particularly in higher socioeconomic segments and among patients with specific comorbidities. The development of more affordable generic versions of advanced oral anti-diabetic drugs can unlock access for a wider patient base.
Growth Accelerators in the Philippines Oral Anti-Diabetic Drug Market Industry
Several catalysts are accelerating the growth of the Philippines oral anti-diabetic drug market. Technological breakthroughs in drug discovery and development are leading to the introduction of novel molecules with improved efficacy and safety profiles, such as dual agonists. Strategic partnerships between multinational pharmaceutical companies and local distributors are enhancing market reach and accessibility. Market expansion strategies, including targeted marketing campaigns and educational programs for healthcare professionals and patients, are playing a crucial role in driving the adoption of advanced oral anti-diabetic therapies. Furthermore, increasing government focus on non-communicable diseases and the development of diabetes management guidelines contribute to a favorable market environment.
Key Players Shaping the Philippines Oral Anti-Diabetic Drug Market Market
- Merck And Co
- Pfizer
- Takeda
- Janssen Pharmaceuticals
- Eli Lilly
- Novartis
- Sanofi
- AstraZeneca
- Bristol Myers Squibb
- Novo Nordisk
- Boehringer Ingelheim
- Astellas
Notable Milestones in Philippines Oral Anti-Diabetic Drug Market Sector
- March 2023: Approval of brolucizumab by the Philippine Food and Drug Administration (FDA) for the treatment of visual impairment caused by diabetic macular edema (DME). This milestone is crucial for addressing a prevalent microvascular complication in diabetic patients and offers significant hope for working-age individuals facing vision loss.
- May 2022: Mounjaro (tirzepatide) injection approved to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Clinical studies demonstrated its superior efficacy compared to other diabetes therapies.
- March 2023: Daewoong Pharmaceutical's Envlo filed for product licenses in Indonesia, the Philippines, and Thailand, signaling its intent for a full-scale global market entry within the ASEAN region.
In-Depth Philippines Oral Anti-Diabetic Drug Market Market Outlook
The Philippines oral anti-diabetic drug market is on a strong growth trajectory, fueled by a widening patient base and an increasing demand for advanced treatment options. The market outlook is characterized by the continued rise of newer drug classes like SGLT2 inhibitors and DPP-4 inhibitors, driven by their demonstrated efficacy and favorable patient outcomes. Strategic collaborations and an emphasis on developing more affordable generic alternatives will be crucial for expanding market access and penetration across diverse socioeconomic strata. The increasing integration of digital health solutions and personalized medicine approaches will further shape the future of diabetes management, presenting significant opportunities for market players to innovate and cater to evolving patient needs. The market is expected to witness sustained growth, driven by proactive healthcare policies and a growing emphasis on preventative care and comprehensive diabetes management.
Philippines Oral Anti-Diabetic Drug Market Segmentation
-
1. Drug Class
- 1.1. Biguanides
- 1.2. Alpha-Glucosidase Inhibitors
- 1.3. Dopamine D2 Receptor Agonist
- 1.4. SGLT2 Inhibitors
- 1.5. DPP-4 Inhibitors
- 1.6. Sulfonylureas
- 1.7. Meglitinides
-
2. Indication
- 2.1. Type 1 Diabetes
- 2.2. Type 2 Diabetes
- 2.3. Gestational Diabetes
Philippines Oral Anti-Diabetic Drug Market Segmentation By Geography
- 1. Philippines
Philippines Oral Anti-Diabetic Drug Market Regional Market Share
Geographic Coverage of Philippines Oral Anti-Diabetic Drug Market
Philippines Oral Anti-Diabetic Drug Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of > 4.00% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Geriatric Population and Changing Dietary Habits; High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation; Development of Latest Drugs and Treatment Procedures
- 3.3. Market Restrains
- 3.3.1. Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs; Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs
- 3.4. Market Trends
- 3.4.1. Sulfonylureas Segment Occupied the Highest Market Share in the Philippines Oral Anti-Diabetic Drugs Market in the current year.
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Philippines Oral Anti-Diabetic Drug Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 5.1.1. Biguanides
- 5.1.2. Alpha-Glucosidase Inhibitors
- 5.1.3. Dopamine D2 Receptor Agonist
- 5.1.4. SGLT2 Inhibitors
- 5.1.5. DPP-4 Inhibitors
- 5.1.6. Sulfonylureas
- 5.1.7. Meglitinides
- 5.2. Market Analysis, Insights and Forecast - by Indication
- 5.2.1. Type 1 Diabetes
- 5.2.2. Type 2 Diabetes
- 5.2.3. Gestational Diabetes
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. Philippines
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 6. Competitive Analysis
- 6.1. Market Share Analysis 2025
- 6.2. Company Profiles
- 6.2.1 Merck And Co
- 6.2.1.1. Overview
- 6.2.1.2. Products
- 6.2.1.3. SWOT Analysis
- 6.2.1.4. Recent Developments
- 6.2.1.5. Financials (Based on Availability)
- 6.2.2 Pfizer
- 6.2.2.1. Overview
- 6.2.2.2. Products
- 6.2.2.3. SWOT Analysis
- 6.2.2.4. Recent Developments
- 6.2.2.5. Financials (Based on Availability)
- 6.2.3 Takeda
- 6.2.3.1. Overview
- 6.2.3.2. Products
- 6.2.3.3. SWOT Analysis
- 6.2.3.4. Recent Developments
- 6.2.3.5. Financials (Based on Availability)
- 6.2.4 Janssen Pharmaceuticals
- 6.2.4.1. Overview
- 6.2.4.2. Products
- 6.2.4.3. SWOT Analysis
- 6.2.4.4. Recent Developments
- 6.2.4.5. Financials (Based on Availability)
- 6.2.5 Eli Lilly
- 6.2.5.1. Overview
- 6.2.5.2. Products
- 6.2.5.3. SWOT Analysis
- 6.2.5.4. Recent Developments
- 6.2.5.5. Financials (Based on Availability)
- 6.2.6 Novartis
- 6.2.6.1. Overview
- 6.2.6.2. Products
- 6.2.6.3. SWOT Analysis
- 6.2.6.4. Recent Developments
- 6.2.6.5. Financials (Based on Availability)
- 6.2.7 Sanofi
- 6.2.7.1. Overview
- 6.2.7.2. Products
- 6.2.7.3. SWOT Analysis
- 6.2.7.4. Recent Developments
- 6.2.7.5. Financials (Based on Availability)
- 6.2.8 AstraZeneca
- 6.2.8.1. Overview
- 6.2.8.2. Products
- 6.2.8.3. SWOT Analysis
- 6.2.8.4. Recent Developments
- 6.2.8.5. Financials (Based on Availability)
- 6.2.9 Bristol Myers Squibb
- 6.2.9.1. Overview
- 6.2.9.2. Products
- 6.2.9.3. SWOT Analysis
- 6.2.9.4. Recent Developments
- 6.2.9.5. Financials (Based on Availability)
- 6.2.10 Novo Nordisk
- 6.2.10.1. Overview
- 6.2.10.2. Products
- 6.2.10.3. SWOT Analysis
- 6.2.10.4. Recent Developments
- 6.2.10.5. Financials (Based on Availability)
- 6.2.11 Boehringer Ingelheim
- 6.2.11.1. Overview
- 6.2.11.2. Products
- 6.2.11.3. SWOT Analysis
- 6.2.11.4. Recent Developments
- 6.2.11.5. Financials (Based on Availability)
- 6.2.12 Astellas
- 6.2.12.1. Overview
- 6.2.12.2. Products
- 6.2.12.3. SWOT Analysis
- 6.2.12.4. Recent Developments
- 6.2.12.5. Financials (Based on Availability)
- 6.2.1 Merck And Co
List of Figures
- Figure 1: Philippines Oral Anti-Diabetic Drug Market Revenue Breakdown (Million, %) by Product 2025 & 2033
- Figure 2: Philippines Oral Anti-Diabetic Drug Market Share (%) by Company 2025
List of Tables
- Table 1: Philippines Oral Anti-Diabetic Drug Market Revenue Million Forecast, by Drug Class 2020 & 2033
- Table 2: Philippines Oral Anti-Diabetic Drug Market Volume K Unit Forecast, by Drug Class 2020 & 2033
- Table 3: Philippines Oral Anti-Diabetic Drug Market Revenue Million Forecast, by Indication 2020 & 2033
- Table 4: Philippines Oral Anti-Diabetic Drug Market Volume K Unit Forecast, by Indication 2020 & 2033
- Table 5: Philippines Oral Anti-Diabetic Drug Market Revenue Million Forecast, by Region 2020 & 2033
- Table 6: Philippines Oral Anti-Diabetic Drug Market Volume K Unit Forecast, by Region 2020 & 2033
- Table 7: Philippines Oral Anti-Diabetic Drug Market Revenue Million Forecast, by Drug Class 2020 & 2033
- Table 8: Philippines Oral Anti-Diabetic Drug Market Volume K Unit Forecast, by Drug Class 2020 & 2033
- Table 9: Philippines Oral Anti-Diabetic Drug Market Revenue Million Forecast, by Indication 2020 & 2033
- Table 10: Philippines Oral Anti-Diabetic Drug Market Volume K Unit Forecast, by Indication 2020 & 2033
- Table 11: Philippines Oral Anti-Diabetic Drug Market Revenue Million Forecast, by Country 2020 & 2033
- Table 12: Philippines Oral Anti-Diabetic Drug Market Volume K Unit Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Philippines Oral Anti-Diabetic Drug Market?
The projected CAGR is approximately > 4.00%.
2. Which companies are prominent players in the Philippines Oral Anti-Diabetic Drug Market?
Key companies in the market include Merck And Co, Pfizer, Takeda, Janssen Pharmaceuticals, Eli Lilly, Novartis, Sanofi, AstraZeneca, Bristol Myers Squibb, Novo Nordisk, Boehringer Ingelheim, Astellas.
3. What are the main segments of the Philippines Oral Anti-Diabetic Drug Market?
The market segments include Drug Class, Indication.
4. Can you provide details about the market size?
The market size is estimated to be USD 202.20 Million as of 2022.
5. What are some drivers contributing to market growth?
Increasing Geriatric Population and Changing Dietary Habits; High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation; Development of Latest Drugs and Treatment Procedures.
6. What are the notable trends driving market growth?
Sulfonylureas Segment Occupied the Highest Market Share in the Philippines Oral Anti-Diabetic Drugs Market in the current year..
7. Are there any restraints impacting market growth?
Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs; Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs.
8. Can you provide examples of recent developments in the market?
March 2023: The approval of brolucizumab by the Philippine Food and Drug Administration (FDA) for the treatment of visual impairment caused by diabetic macular edema (DME) is a major achievement. DME is a prevalent microvascular complication in diabetic patients that can severely affect their vision and potentially result in blindness. This milestone is particularly significant for working-age individuals with DME, as they often face challenges in adhering to treatment due to the management of various diabetes-related conditions.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 3800, USD 4500, and USD 5800 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Philippines Oral Anti-Diabetic Drug Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Philippines Oral Anti-Diabetic Drug Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Philippines Oral Anti-Diabetic Drug Market?
To stay informed about further developments, trends, and reports in the Philippines Oral Anti-Diabetic Drug Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence